0001104659-20-130082.txt : 20201127
0001104659-20-130082.hdr.sgml : 20201127
20201127171024
ACCESSION NUMBER: 0001104659-20-130082
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201124
FILED AS OF DATE: 20201127
DATE AS OF CHANGE: 20201127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perry George
CENTRAL INDEX KEY: 0001725758
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38045
FILM NUMBER: 201355841
MAIL ADDRESS:
STREET 1: C/O NEUROTROPE, INC.
STREET 2: 205 EAST 42ND STREET, 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neurotrope, Inc.
CENTRAL INDEX KEY: 0001513856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463522381
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: (973) 242-0005
MAIL ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: BlueFlash Communications, Inc.
DATE OF NAME CHANGE: 20110223
4
1
tm2037145d8_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2020-11-24
0
0001513856
Neurotrope, Inc.
NTRP
0001725758
Perry George
C/O NEUROTROPE, INC.
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Stock Option (right to buy)
0.972
2020-11-24
4
A
0
15000
0
A
2030-11-24
Common Stock
15000
15000
D
The shares will immediately vest and become exercisable subject to and upon consummation of (1) the merger of PM Merger Sub 1, LLC with and into Metuchen Pharmaceuticals, LLC ("Metuchen"), with Metuchen surviving as a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. ("Petros") and (2) the merger of PN Merger Sub 2, Inc. with and into Neurotrope, Inc. ("Neurotrope"), with Neurotrope surviving as a wholly-owned subsidiary of Petros (together, the "Mergers").
In the event the reporting person departs from the board of directors following the consummation of the Mergers, the options shall expire on the date that is one year from the date of the consummation of the Mergers.
/s/ Robert Weinstein, Attorney-in-Fact
2020-11-27